Cargando…

Multi-Chemotherapeutic Schedules Containing the pan-FGFR Inhibitor ARQ 087 are Safe and Show Antitumor Activity in Different Xenograft Models()

ARQ 087 is a multi-tyrosine kinase inhibitor with potent activity against the FGFR receptor family, currently in Phase I clinical studies for the treatment of advanced solid tumors. The compound has a very safe profile and induces tumor regressions in FGFR-driven models. The feasibility of combining...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chilà, Rosaria, Hall G., Terence, Abbadessa, Giovanni, Broggini, Massimo, Damia, Giovanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2017
Materias:	Short communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5293737/ https://www.ncbi.nlm.nih.gov/pubmed/28161661 http://dx.doi.org/10.1016/j.tranon.2016.12.003

Ejemplares similares

In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor
por: Yu, Yi, et al.
Publicado: (2017)

Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation
por: Hall, Terence G., et al.
Publicado: (2016)

A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours
por: Papadopoulos, K P, et al.
Publicado: (2017)

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
por: Mazzaferro, Vincenzo, et al.
Publicado: (2018)

Combination of the c-Met Inhibitor Tivantinib and Zoledronic Acid Prevents Tumor Bone Engraftment and Inhibits Progression of Established Bone Metastases in a Breast Xenograft Model
por: Previdi, Sara, et al.
Publicado: (2013)

Transmission of the atypical/Nor98 scrapie agent to Suffolk sheep with VRQ/ARQ, ARQ/ARQ, and ARQ/ARR genotypes
por: Cassmann, Eric D., et al.
Publicado: (2021)

SUN-087 FGFR-Selective Tyrosine Kinase Inhibitors, Such as Infigratinib, Show Potency and Selectivity for FGFR3 at Pharmacologically Relevant Doses for the Potential Treatment of Achondroplasia
por: Dobscha, Katherine, et al.
Publicado: (2020)

Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
por: Yu, Yi, et al.
Publicado: (2015)

In vivo efficacy of the AKT inhibitor ARQ 092 in Noonan Syndrome with multiple lentigines-associated hypertrophic cardiomyopathy
por: Wang, Jianxun, et al.
Publicado: (2017)

Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models
por: Grünewald, Sylvia, et al.
Publicado: (2019)

ARQ20 : arquitectura en la España del siglo XX /
Publicado: (2006)

ARQ20 : arquitectura en la España del siglo XX.
Publicado: (2012)

Overcoming platinum-acquired resistance in ovarian cancer patient-derived xenografts
por: Ricci, Francesca, et al.
Publicado: (2019)

In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models()()
por: Guffanti, Federica, et al.
Publicado: (2016)

Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts
por: Ricci, Francesca, et al.
Publicado: (2017)

A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis
por: Santoro, A, et al.
Publicado: (2013)

ARQ-197 enhances the antitumor effect of sorafenib in hepatocellular carcinoma cells via decelerating its intracellular clearance
por: Gao, Xudong, et al.
Publicado: (2019)

Transmission of atypical scrapie to homozygous ARQ sheep
por: OKADA, Hiroyuki, et al.
Publicado: (2016)

Analysis of channel uncertainty in ARQ relay networks
por: Ajmal, Hina, et al.
Publicado: (2018)

Index Coded Automatic Repeat Request (ARQ)
por: Choi, Sang Won
Publicado: (2020)

AB087. The biotherapy for bladder cancer
por: Wang, Zhiping
Publicado: (2015)

Feinix-Arq: distribución GNU/LINUX a medida para la Facultad de Arquitectura de la Universidad Veracruzana /
por: Martínez Tovar, Víctor Daniel
Publicado: (2007)

Strain Typing of Classical Scrapie and Bovine Spongiform Encephalopathy (BSE) by Using Ovine PrP (ARQ/ARQ) Overexpressing Transgenic Mice
por: Fatola, Olanrewaju I., et al.
Publicado: (2022)

Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage
por: Yamamoto, Yuji, et al.
Publicado: (2014)

Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma
por: Jilkova, Zuzana Macek, et al.
Publicado: (2018)

Infigratinib (BGJ 398), a Pan-FGFR Inhibitor, Targets P-Glycoprotein and Increases Chemotherapeutic-Induced Mortality of Multidrug-Resistant Tumor Cells
por: Boichuk, Sergei, et al.
Publicado: (2022)

Macintosh in the laboratory (CERN-PRE-87-087)
por: Taylor, B G
Publicado: (1987)

Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma
por: Personeni, Nicola, et al.
Publicado: (2017)

Activity of Pan-Class I Isoform PI3K/mTOR Inhibitor PF-05212384 in Combination with Crizotinib in Ovarian Cancer Xenografts and PDX()
por: Iezzi, Alice, et al.
Publicado: (2016)

Location Distribution of 2,087 Osteochondral Lesions of the Talus
por: van Diepen, Pascal R., et al.
Publicado: (2020)

Radiosensitization by the Selective Pan-FGFR Inhibitor LY2874455
por: Darwis, Narisa Dewi Maulany, et al.
Publicado: (2022)

Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts
por: Guffanti, Federica, et al.
Publicado: (2018)

Hybrid ARQ Scheme with Autonomous Retransmission for Multicasting in Wireless Sensor Networks
por: Jung, Young-Ho, et al.
Publicado: (2017)

ARQ531: the therapy that targets multiple pathways in acute myeloid leukemia
por: Hellmich, Charlotte, et al.
Publicado: (2020)

Identification of PLK1 as a New Therapeutic Target in Mucinous Ovarian Carcinoma
por: Affatato, Roberta, et al.
Publicado: (2020)

Structural insights into the potency and selectivity of covalent pan-FGFR inhibitors
por: Qu, Lingzhi, et al.
Publicado: (2022)

Crystal Structure of the FGFR4/LY2874455 Complex Reveals Insights into the Pan-FGFR Selectivity of LY2874455
por: Wu, Daichao, et al.
Publicado: (2016)

BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression
por: Kim, Se Hyun, et al.
Publicado: (2018)

The new small tyrosine kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs
por: Soncini, Debora, et al.
Publicado: (2019)

Stable CDK12 Knock-Out Ovarian Cancer Cells Do Not Show Increased Sensitivity to Cisplatin and PARP Inhibitor Treatment
por: Chilà, Rosaria, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_20rpt1l1t2rd3mrpkq5f9pnrjh